Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kristina Engvall"'
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-9 (2024)
Abstract Persistent taxane-induced peripheral neuropathy (TIPN) is highly prevalent among early-stage breast cancer survivors (ESBCS) and has detrimental effect on quality of life. We leveraged logistic regression models to develop and validate polyg
Externí odkaz:
https://doaj.org/article/208fc9bd2b314412838db7fc5838e614
Autor:
Sander Ellegård, Kristina Engvall, Mustafa Asowed, Anna-Lotta Hallbeck, Nils Elander, Olle Stål
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionSince its introduction in standard of care, trastuzumab has revolutionized the treatment of patients with early and late stages of HER2-positive breast cancer. While the initial clinical trials were convincing and lead to major changes in
Externí odkaz:
https://doaj.org/article/b14f3d05c80248c9b2c9ce859278c793
Autor:
Kristina Engvall, Henrik Gréen, Mats Fredrikson, Magnus Lagerlund, Freddi Lewin, Elisabeth Åvall-Lundqvist
Background We explored the impact of persistent sensory and motor taxane-induced peripheral neuropathy (TIPN) symptoms on health-related quality of life (HRQL) among early-stage breast cancer survivors (ESBCS). Methods A population-based cohort of 88
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c291e1ccd0c74373dd76dded2c239dc
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-187717
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-187717
Publikováno v:
Br J Cancer
BACKGROUND: The prevalence of persistent peripheral neuropathy (PN) in early-stage breast cancer (ESBC) survivors is largely unknown. We explored the occurrence and risk factors of PN among long-term ESBC survivors treated with taxane chemotherapy. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0acce94a0fe7099c56d5dfa225fdb7f6
https://europepmc.org/articles/PMC8329002/
https://europepmc.org/articles/PMC8329002/